One Za’abeel’s Coveted One&Only Private Homes and ‘The Residences’ Are Now Available for Sale, Announces Ithra Dubai
8.6.2022 07:30:00 EEST | Business Wire | Press release
Ithra Dubai, a leading real estate developer and asset manager, wholly owned by Investment Corporation of Dubai, announced the highly anticipated sale of One Za’abeel’s One&Only Private Homes and The Residences in Dubai’s most iconic address.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005001/en/
One Za’abeel, the multi-award-winning mixed-used development, is destined to become one of the UAE’s most recognizable architectural icons located right in Dubai’s business center. A marvel of engineering with the world’s longest cantilevered building, it is set to be awarded a GUINNESS WORLD RECORD™.
Suspended perpendicularly across the two towers at a height of around 100 meters and weighing 13,000 tonnes, The Link will host several engaging experiences and will include captivating entertainment venues, dining with celebrity chefs, an infinity pool, an observation deck with uninterrupted 360˚views of Dubai, and an immersive glass-floor experience.
One Za’abeel Tower offers 94 One&Only Private Homes for sale, the pinnacle of urban living in the world’s first vertical urban resort managed by the ultra-luxury One&Only brand. Located in some of the world’s most sought-after destinations, One&Only Private Homes offer upscale private residential sanctuaries with One Za’abeel being no exception. Reflecting the architecture, design, and lifestyle elements for which One&Only is celebrated, One&Only Private Homes offer unparalleled access to the luxury hospitality collection’s world-class resorts, in addition to a series of exclusive benefits.
One Za’abeel’s The Residences houses 264 apartments with a strategic location and lavish facilities. The residences for sale include 1, 2, 3, and 4-bedroom simplexes and duplexes and a 5-bedroom penthouse.
Available for lease in this mixed-use masterpiece is deluxe office space covering an area of 26,000 square and three floors of retail space, F&B, and leisure experiences at the Podium, covering an area of 12,000 square meters.
Strategically located in the heart of the city, at the intersection of Dubai’s famous Sheikh Zayed Road and its commercial business district, One Za’abeel is the gateway to Dubai International Financial District, close to Dubai World Trade Centre, Burj Khalifa, and Dubai International Airport.
“With its mesmerizing architecture, central location, and exceptional mix of offerings, One Za’abeel is an exceptional place to live, work, and spend leisure time in one of Dubai’s most desirable addresses, a true reflection of Dubai’s ambitious spirit,” said Issam Galadari, Director and CEO of Ithra Dubai.
In line with the UAE’s net-zero target for 2050, the development aims to achieve the highest standards of sustainability as it implements the Gold LEED certification requirements in its design and functionality.
About Ithra Dubai
Ithra Dubai LLC, wholly owned by Investment Corporation of Dubai (ICD), develops and manages a portfolio of pioneering real estate projects in Dubai and in key international markets. Its projects are designed to embrace diversity, shape happy communities, and bring prosperity to many. Ithra Dubai aims to deliver mixed-used developments on an ambitious scale, which incorporates world-class retail, commercial, residential, and leisure concepts.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005001/en/
Contact information
Yara Bou Hadir
pressenquiries@sabaconsultants.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom